Schrödinger, Inc.
HealthcareNASDAQ:SDGR · NASDAQ Global Select
-$0.15 today
Vol 0.86M · Avg 1.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.4%
avg -1.8%
ROIC
-30.2%
avg -27.5%
ROA
-14.2%
avg -15.5%
Analysis
ROA is currently the strongest return metric at -14.2% versus its period average of -15.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ramy Farid | Chief Executive Officer, President & Director | $1.32M | — | 61 | $373,824.00 | 0.50% |
Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships | $944,225.00 | — | 58 | $69,956.00 | 0.09% |
Yvonne Tran | Corporate Secretary, Chief Legal & People Officer | $867,447.00 | — | 55 | $52,683.00 | 0.07% |
Richie Jain | Executive Vice President, Chief Financial Officer & Treasurer | $747,954.00 | — | 41 | $51,752.00 | 0.07% |
Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software | $736,839.00 | — | 42 | $89,241.00 | 0.12% |
Robert Lorne Abel | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D | $736,839.00 | — | 44 | $55,897.00 | 0.07% |
Mannix Aklian | Executive VP, Chief Commercial Officer and Global Head of Software Sales & Marketing | $556,190.00 | — | 51 | $84,375.00 | 0.11% |
Richard A. Friesner | Co-Founder, Scientific Advisory Chairman and Director | $486,800.00 | — | 73 | $521,697.00 | 0.70% |
Matt Repasky | Senior Vice President of Life Sciences Products | — | — | — | — | — |
Lingle Wang | Senior Vice President of Scientific Development | — | — | — | — | — |
Mathew D. Halls | Senior Vice President of Materials Science | — | — | — | — | — |
Mike Beachy | Senior Vice President of Software Development | — | — | — | — | — |
Shane Brauner | Executive Vice President & Chief Information Officer | — | — | 49 | $15,000.00 | 0.02% |
Nathalie Lacoste | Senior Vice President of Life Science Business | — | — | — | — | — |
Therese Abrams | Principal Accounting Officer | — | — | 42 | $0.00 | <0.01% |
William Goddard | Co-Founder & Scientific Advisor | — | — | — | — | — |
Duncan Hamish Wright | Senior Vice President of Translational Science & Therapeutics Business Development | — | — | — | — | — |
Jaren Irene Madden | Chief Corporate Affairs Officer & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$1.30M
Net Sentiment
$1.30M
Net selling
Most Active
Farid Ramy
3 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $1.30M over the last 12 months. That adds up to net selling of $1.30M. Farid Ramy was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +27.4% | +12.8% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.4% over three years. Forward estimates point to Revenue at +12.8% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Omada Health
NASDAQ:OMDA
$1.02B
Evotec SE
NASDAQ:EVO
$966.11M
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages SDGR?
Schrödinger, Inc. (SDGR) lists 18 active executives. The top listed executive is Yvonne Tran, Corporate Secretary, Chief Legal & People Officer.
Are SDGR insiders buying or selling?
Recent insider activity shows net buying of $47.10M.
Explore More
Continue the stock analysis
Jump to another research area for this company.